Acute and long-term effects of nateglinide on insulin secretory pathways

AJ Ball, Peter Flatt, Neville McClenaghan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

1 Acute and chronic effects of the insulinotropic drug nateglinide upon insulin release were examined in the BRIM-BD11 cell line. 2 Nateglinide (10-400 muM) stimulated a concentration-dependent increase (P <0.05-P <0.001) in insulin release at a non-stimulatory (1.1 mM) glucose concentration. The insulinotropic response to 200 muM nateglinide was increased at 30 mM (P <0.01), but not 5.6-16.7 mM glucose concentrations. 3 In depolarized cells, nateglinide (50-200 muM) evoked K-ATP channel-independent insulin secretion (P <0.05-P <0.001) in the absence and presence of 5.6-30.0 mM glucose (P <0.001). 4 Exposure for 18h to 100 muM nateglinide abolished the acute insulinotropic effects of 200 muM nateglinide, tolbutamide or glibenclamide, but had no effect upon the insulinotropic effect of 200 muM efaroxan. 5 While 18h exposure to 100 muM nateglinide did not affect basal insulin release or insulin release in the presence of 16.7 mM glucose, 25 muM forskolin or 10 nM PMA, significant inhibition of the insulinotropic effects of 20 aim leucine and Maim arginine were observed. 6 These data show that nateglinide stimulates both K-ATP channel-dependent and-independent insulin secretion. The maintained insulinotropic effects of this drug with increasing glucose concentrations support the antihyperglycaemic actions of nateglinide in Type II diabetes. 7 Studies of the long-term effects of nateglinide indicate that nateglinide shares signalling pathways with sulphonylureas, but not the imidazoline efaroxan. This may be significant when considering a nateglinide treatment regimen, particularly in patients previously treated with sulphonylurea.
LanguageEnglish
Pages367-373
JournalBritish Journal of Pharmacology
Volume142
Issue number2
DOIs
Publication statusPublished - May 2004

Fingerprint

nateglinide
Secretory Pathway
Insulin
efaroxan
Glucose
Adenosine Triphosphate
Imidazolines
Tolbutamide

Cite this

Ball, AJ ; Flatt, Peter ; McClenaghan, Neville. / Acute and long-term effects of nateglinide on insulin secretory pathways. In: British Journal of Pharmacology. 2004 ; Vol. 142, No. 2. pp. 367-373.
@article{2346de9e494e49e09ae9b9bc309a1952,
title = "Acute and long-term effects of nateglinide on insulin secretory pathways",
abstract = "1 Acute and chronic effects of the insulinotropic drug nateglinide upon insulin release were examined in the BRIM-BD11 cell line. 2 Nateglinide (10-400 muM) stimulated a concentration-dependent increase (P <0.05-P <0.001) in insulin release at a non-stimulatory (1.1 mM) glucose concentration. The insulinotropic response to 200 muM nateglinide was increased at 30 mM (P <0.01), but not 5.6-16.7 mM glucose concentrations. 3 In depolarized cells, nateglinide (50-200 muM) evoked K-ATP channel-independent insulin secretion (P <0.05-P <0.001) in the absence and presence of 5.6-30.0 mM glucose (P <0.001). 4 Exposure for 18h to 100 muM nateglinide abolished the acute insulinotropic effects of 200 muM nateglinide, tolbutamide or glibenclamide, but had no effect upon the insulinotropic effect of 200 muM efaroxan. 5 While 18h exposure to 100 muM nateglinide did not affect basal insulin release or insulin release in the presence of 16.7 mM glucose, 25 muM forskolin or 10 nM PMA, significant inhibition of the insulinotropic effects of 20 aim leucine and Maim arginine were observed. 6 These data show that nateglinide stimulates both K-ATP channel-dependent and-independent insulin secretion. The maintained insulinotropic effects of this drug with increasing glucose concentrations support the antihyperglycaemic actions of nateglinide in Type II diabetes. 7 Studies of the long-term effects of nateglinide indicate that nateglinide shares signalling pathways with sulphonylureas, but not the imidazoline efaroxan. This may be significant when considering a nateglinide treatment regimen, particularly in patients previously treated with sulphonylurea.",
author = "AJ Ball and Peter Flatt and Neville McClenaghan",
year = "2004",
month = "5",
doi = "10.1038/sj.bjp.0705766",
language = "English",
volume = "142",
pages = "367--373",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
number = "2",

}

Acute and long-term effects of nateglinide on insulin secretory pathways. / Ball, AJ; Flatt, Peter; McClenaghan, Neville.

In: British Journal of Pharmacology, Vol. 142, No. 2, 05.2004, p. 367-373.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Acute and long-term effects of nateglinide on insulin secretory pathways

AU - Ball, AJ

AU - Flatt, Peter

AU - McClenaghan, Neville

PY - 2004/5

Y1 - 2004/5

N2 - 1 Acute and chronic effects of the insulinotropic drug nateglinide upon insulin release were examined in the BRIM-BD11 cell line. 2 Nateglinide (10-400 muM) stimulated a concentration-dependent increase (P <0.05-P <0.001) in insulin release at a non-stimulatory (1.1 mM) glucose concentration. The insulinotropic response to 200 muM nateglinide was increased at 30 mM (P <0.01), but not 5.6-16.7 mM glucose concentrations. 3 In depolarized cells, nateglinide (50-200 muM) evoked K-ATP channel-independent insulin secretion (P <0.05-P <0.001) in the absence and presence of 5.6-30.0 mM glucose (P <0.001). 4 Exposure for 18h to 100 muM nateglinide abolished the acute insulinotropic effects of 200 muM nateglinide, tolbutamide or glibenclamide, but had no effect upon the insulinotropic effect of 200 muM efaroxan. 5 While 18h exposure to 100 muM nateglinide did not affect basal insulin release or insulin release in the presence of 16.7 mM glucose, 25 muM forskolin or 10 nM PMA, significant inhibition of the insulinotropic effects of 20 aim leucine and Maim arginine were observed. 6 These data show that nateglinide stimulates both K-ATP channel-dependent and-independent insulin secretion. The maintained insulinotropic effects of this drug with increasing glucose concentrations support the antihyperglycaemic actions of nateglinide in Type II diabetes. 7 Studies of the long-term effects of nateglinide indicate that nateglinide shares signalling pathways with sulphonylureas, but not the imidazoline efaroxan. This may be significant when considering a nateglinide treatment regimen, particularly in patients previously treated with sulphonylurea.

AB - 1 Acute and chronic effects of the insulinotropic drug nateglinide upon insulin release were examined in the BRIM-BD11 cell line. 2 Nateglinide (10-400 muM) stimulated a concentration-dependent increase (P <0.05-P <0.001) in insulin release at a non-stimulatory (1.1 mM) glucose concentration. The insulinotropic response to 200 muM nateglinide was increased at 30 mM (P <0.01), but not 5.6-16.7 mM glucose concentrations. 3 In depolarized cells, nateglinide (50-200 muM) evoked K-ATP channel-independent insulin secretion (P <0.05-P <0.001) in the absence and presence of 5.6-30.0 mM glucose (P <0.001). 4 Exposure for 18h to 100 muM nateglinide abolished the acute insulinotropic effects of 200 muM nateglinide, tolbutamide or glibenclamide, but had no effect upon the insulinotropic effect of 200 muM efaroxan. 5 While 18h exposure to 100 muM nateglinide did not affect basal insulin release or insulin release in the presence of 16.7 mM glucose, 25 muM forskolin or 10 nM PMA, significant inhibition of the insulinotropic effects of 20 aim leucine and Maim arginine were observed. 6 These data show that nateglinide stimulates both K-ATP channel-dependent and-independent insulin secretion. The maintained insulinotropic effects of this drug with increasing glucose concentrations support the antihyperglycaemic actions of nateglinide in Type II diabetes. 7 Studies of the long-term effects of nateglinide indicate that nateglinide shares signalling pathways with sulphonylureas, but not the imidazoline efaroxan. This may be significant when considering a nateglinide treatment regimen, particularly in patients previously treated with sulphonylurea.

U2 - 10.1038/sj.bjp.0705766

DO - 10.1038/sj.bjp.0705766

M3 - Article

VL - 142

SP - 367

EP - 373

JO - British Journal of Pharmacology

T2 - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -